scholarly journals Successful twice interrupted therapy of HCV infection in patients with cirrhosis with hepatocellular carcinoma before and after liver transplantation

2017 ◽  
pp. bcr-2017-220152 ◽  
Author(s):  
Anna Szymanek-Pasternak ◽  
Karolina Rostkowska ◽  
Krzysztof Simon
Author(s):  
D. V. Umrik ◽  
O. M. Tsiroulnikova ◽  
I. A. Miloserdov ◽  
R. A. Latypov ◽  
E. T. Egorova

HCV infection is one of the most common causes leading to the development of terminal liver diseases – cirrhosis and hepatocellular carcinoma, the main treatment for which is orthotopic liver transplantation. However, with continued virus replication, 100% reinfection occurs, which leads to the rapid progression of cirrhosis of the graft and the loss of its function. Standard interferon-containing therapy is ineffective for HCV infection, especially genotype 1, both before and after transplantation, and also has a wide range of adverse events. The article presents the successful experience of treating the recurrence of HCV infection 1 genotype in a patient who underwent liver transplantation and several courses of ineffective antiviral therapy.


2017 ◽  
Vol 11 (3) ◽  
pp. 701-710 ◽  
Author(s):  
Yumiko Nagao ◽  
Kazunori Nakasone ◽  
Tatsuji Maeshiro ◽  
Nao Nishida ◽  
Kanae Kimura ◽  
...  

Hepatitis C virus (HCV) infection is frequently associated with various extrahepatic manifestations, such as autoimmune features and immune complex deposit diseases. Oral lichen planus (OLP) is one such extrahepatic manifestation of HCV infection. Recently, direct-acting antivirals (DAA) have proved to be highly effective and safe for the eradication of HCV. Herein, we report a case of OLP accompanied by HCV-related hepatocellular carcinoma (HCC) that disappeared after liver transplantation and achievement of sustained virological response following interferon (IFN)-free treatment with ledipasvir (LDV) and sofosbuvir (SOF). The 50-year-old patient developed erosive OLP during IFN therapy, with hyperthyroidism at 53 years of age and HCC at 55 years. He received immunosuppressive drugs and IFN-free DAA treatment after liver transplantation at 60 years of age, which led to disappearance of the symptoms of OLP. The patient was treated safely and effectively with LDV/SOF, although it is not known whether the disappearance of OLP resulted from the eradication of HCV or the immunosuppressive therapy.


2019 ◽  
Vol 85 (8) ◽  
pp. 900-903
Author(s):  
Venkat Sumanth Potluri ◽  
Julio Sokolich ◽  
Jacentha Buggs ◽  
William Mcclellan ◽  
Ebonie Rogers ◽  
...  

The United Network for Organ Sharing (UNOS) implemented a policy that requires patients with hepatocellular carcinoma seeking liver transplantation to wait six months before being granted Model for End-Stage Liver Disease exception points. We investigated the difference in resource utilization between patients who underwent liver transplantation before and after the present policy. We conducted a retrospective cohort study of adult liver transplants from 2013 to 2018. Patients were classified into prepolicy or postpolicy groups based on 964 days before or after the wait-time policy. We also retrieved national survival outcome data from United Network for Organ Sharing. Differences across compared groups for continuous variables were assessed using the independent sample t test, and the chi-squared test was used for binary variables. We found statistical differences in recipient age ( P = 0.005), days on wait-list ( P = 0.001), sustained viro-logical response ( P < 0.001), and hepatocellular carcinoma recurrence one year posttransplant ( P = 0.04). There were statistically significant differences in the number of treatment days pretransplant and length of transplant admission stay, indicating an increase in resource utilization in the postpolicy group. No statistically significant differences were found between groups in one-year graft or patient survival despite an observed increase in resource utilization by the hepatocellular carcinoma postpolicy group.


2011 ◽  
Vol 140 (5) ◽  
pp. S-901
Author(s):  
Mario Angelico ◽  
Umberto Cillo ◽  
Stefano Fagiuoli ◽  
Mario Strazzabosco ◽  
Antonio Gasbarrini ◽  
...  

2015 ◽  
Vol 133 (6) ◽  
pp. 525-530 ◽  
Author(s):  
Lucas Carvalho Dantas ◽  
Tércio Genzini ◽  
Marcelo Perosa de Miranda ◽  
Regina Gomes dos Santos ◽  
Nilton Ghiotti de Siqueira ◽  
...  

CONTEXT: Orthotopic liver transplantation (OLT) is the treatment of choice for end-stage liver disease. Cirrhosis due to hepatitis C infection is the leading indication for liver transplantation worldwide. However, patients who are given transplants because of viral liver diseases often present clinical coinfections, including hepatitis B together with hepatitis D. Currently, different strategies exist for patient management before and after liver transplantation, and these are based on different protocols developed by the specialized transplantation centers. CASE REPORT: We present a rare case of a 58-year-old man with chronic hepatitis B, C and D coinfection. The patient developed cirrhosis and hepatocellular carcinoma. His treatment comprised antiviral therapy for the three viruses and OLT. The patient's outcome was satisfactory. CONCLUSION: OLT, in association with antiviral therapy using entecavir, which was administered before and after transplantation, was effective for sustained clearance of the hepatitis B and D viruses. A recurrence of hepatitis C infection after transplantation responded successfully to standard treatment comprising peginterferon alfa-2A and ribavirin.


Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 4056-4056
Author(s):  
Charis von Auer ◽  
Sandra Heinsdorf ◽  
Manuela Krause ◽  
Wolfgang Miesbach ◽  
Inge Scharrer

Abstract Hepatitis C virus (HCV) infection is often observed in hemophilic patients who were treated with non-virus inactivated clotting factor concentrates prior to the mid 1980s. HCV infected patients exhibit an increased risk of developing liver cirrhosis and hepatocellular carcinoma (HCC). Hemophilia cohort studies until 2004 suggest a prevalence of HCC development of 0,1–0,2% in HCV infected hemophilic patients. During the last two years we observed a rapid increase in HCC development in our hemophilia treatment center. In the current study we analyzed our data to investigate the impact of chronic HCV infection in hemophilic patients today. We treated 90 hemophiliacs with chronic HCV hepatitis. Seven of these patients (6,3%) developed a HCC between 2002 and 2005, six of them only between 2004 and 2005. Five patients had severe hemophilia A, one mild hemophilia A, one severe hemophilia B, two of them had co-infections (HIV and HIV+HBV). Three had HCV genotype 1b, three 3a and one unknown. Four had been treated with interferon alpha/peginterferon alone or in combination with ribavirin, only one achieved a virologic response. Two patients refused treatment of HCV infection, one patient was not treated due to HIV co-infection. Their age at HCC diagnosis ranged from 40 to 73 years (median 60), time-course between estimated HCV infection and HCC development ranged between 11 and 35 years (median 22). All patients had developed liver cirrhosis: two Child-Pugh A, one Child-Pugh B and four Child-Pugh C. Six patients were asymptomatic; only one patient had jaundice when HCC was detected. All were regularly checked at least once a year with routine screening of AFP level and ultrasound (US) scans. Three patients had normal, four elevated AFP levels (&gt;15ng/ml), three had US scans without pathological finding when HCC was detected. All had consistently or intermittently elevated serum ALT levels during the last five years before diagnosis. HCC was diagnosed either by elevated AFP levels plus US identification (2) or plus MRT (2), by MRT plus check of arterial hypervascularisation (1) plus liver biopsy (1). One patient was only diagnosed after liver transplantation for chronic liver disease. Orthotopic liver transplantation was done in one patient, transcatheter arterial chemoembolization (TACE) in three, two patients have died of liver failure. Our data show that at present HCC is an increasingly frequent cause of mortality in hemophilic patients with chronic HCV infection. The detection of six HCC in only 15 months is striking. Especially nowadays a close follow up on hemophilic patients with chronic HCV infection seems to be mandatory. This should result in earlier detection and consequently more easily treatable tumors and longer survival of our patients.


Sign in / Sign up

Export Citation Format

Share Document